Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Preferred Stock Liabilities: 2019

Historic Preferred Stock Liabilities for Beam Therapeutics (BEAM) over the last 1 years, with Dec 2019 value amounting to $302.0 million.

  • Beam Therapeutics' Preferred Stock Liabilities was N/A to $302.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $302.0 million, marking a year-over-year change of. This contributed to the annual value of $302.0 million for FY2019, which is N/A change from last year.
  • As of Q4 2019, Beam Therapeutics' Preferred Stock Liabilities stood at $302.0 million, which was up 1.10% from $298.8 million recorded in Q3 2019.
  • Beam Therapeutics' 5-year Preferred Stock Liabilities high stood at $302.0 million for Q4 2019, and its period low was $292.3 million during Q1 2019.
  • Moreover, its 1-year median value for Preferred Stock Liabilities was $297.1 million (2019), whereas its average is $297.2 million.